**Proteins** 

## **DENV-IN-6**

Cat. No.: HY-143273 CAS No.: 2375780-95-1 Molecular Formula:  $C_{23}H_{26}CIFN_4OS$ 

Molecular Weight: 461

Target: HIV; DNA/RNA Synthesis

Pathway: Anti-infection; Cell Cycle/DNA Damage

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description DENV-IN-6 is a potent DENV (I-IV) inhibitor with EC $_{50}$ s of 17.5, 13.20, 6.8 and 11.41  $\mu$ M for the inhibition of DENV (I-IV) replication, respectively. DENV-IN-6 also exhibits activity of anti-HIV-1 $_{\text{IIIB}}$  (EC $_{50}$ =0.0181  $\mu$ M; CC $_{50}$ =64.92  $\mu$ M) $^{[1]}$ .

IC<sub>50</sub> & Target HIV (IIIB)

In Vitro

DENV-IN-6 (compound 4a)  $(0.04, 0.2, 1, 5, 25 \mu \text{M}; 5 \text{ days})$  shows inhibitory effect on replication of DENV (I-IV) in a dosedependent manner (EC<sub>50</sub>s=17.5, 13.20, 6.8 and 11.41  $\mu$ M, respectively)<sup>[1]</sup>.

DENV-IN-6 (25 μM; 5 days) shows low toxic to Vero cells (CC<sub>50</sub>Δ200 μM) and exhibits stronger inhibitory effect on DENV-III than on DENV-I, II, IV with a TI value is greater than 29.41 (Therapeutic index (TI): ratio  $CC_{50}/IC_{50})^{[1]}$ .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay<sup>[1]</sup>

Cell Line:	Vero cells
Concentration:	0.04, 0.2, 1, 5, 25 μM
Incubation Time:	5 days
Result:	Surpressed replication of DENV (I-IV) in a dose-dependent manner and with EC $_{50} s$ of 17.5, 13.20, 6.8 and 11.41 $\mu M$ , respectively.
Cell Cytotoxicity Assay <sup>[1]</sup>	

Cell Cytotoxicity Assays -	
Cell Line:	Vero cells
Concentration:	25 μΜ
Incubation Time:	5 days
Result:	Exhibited low toxic to Vero cells with a CC <sub>50</sub> value was greater than 200 μM. Showed stronger inhibitory effect on DENV-III than on DENV-I, II, IV (Therapeutic index (TI) values of DENV (I-IV): Δ11.43, Δ15.15, Δ29.41, Δ17.53).
	values of DEINV (1-10). MID. 13, MID. 13, MID. 13, MID. 13).

FERENCES	
Rui RM, et al. C6-structura	l optimizations of 2-aryl-1H-pyrazole-S-DABOs: From anti-HIV to anti-DENV activity. Bioorg Chem. 2022 Feb;119:105494.
	Caution: Product has not been fully validated for medical applications. For research use only.
	Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com  Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com